FDA Lifts Partial Clinical Hold on Innate Pharma's Lacutamab IND
Ticker: IPHYF · Form: 6-K · Filed: Jan 5, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Jan 5, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: regulatory-update, clinical-trials, biotech, drug-development
TL;DR
**FDA lifted the partial clinical hold on Innate Pharma's lacutamab, clearing a path for trials to resume.**
AI Summary
Innate Pharma SA announced on January 4, 2024, that the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold on its lacutamab investigational new drug (IND). This hold was initially placed on October 5, 2023, following a patient death in the Phase 2 TELLOMAK and Phase 1b PTCL trials, which was initially suspected to be due to hemophagocytic lymphohistiocytosis (HLH). The FDA's decision to lift the hold came after a review, concluding the patient's death was due to aggressive disease progression and not related to lacutamab, which is crucial for investors as it allows the clinical trials to resume, potentially accelerating the drug's path to market and impacting the company's future revenue prospects.
Why It Matters
This news is significant because it removes a major regulatory hurdle for Innate Pharma's key drug candidate, lacutamab, allowing its clinical trials to proceed and potentially bringing it closer to commercialization.
Risk Assessment
Risk Level: medium — While the hold is lifted, the initial patient death and the temporary halt introduce some lingering uncertainty and scrutiny for the drug's safety profile.
Analyst Insight
A smart investor would view the lifting of the clinical hold as a positive de-risking event for Innate Pharma's lead asset, lacutamab, and might consider this an opportune time to evaluate or increase their position, given the removal of a significant regulatory overhang.
Key Players & Entities
- Innate Pharma SA (company) — registrant and developer of lacutamab
- U.S. Food and Drug Administration (FDA) (company) — regulatory body that placed and lifted the clinical hold
- lacutamab (drug) — investigational new drug (IND) subject to the clinical hold
- October 5, 2023 (date) — date the partial clinical hold was announced
- January 4, 2024 (date) — date the partial clinical hold was lifted
- IPH4102-201 (Phase 2 TELLOMAK) (trial) — one of the ongoing lacutamab trials affected by the hold
- 102 (Phase 1b PTCL) (trial) — one of the ongoing lacutamab trials affected by the hold
- Sézary Syndrome (medical_condition) — condition of the patient whose death led to the hold
- hemophagocytic lymphohistiocytosis (HLH) (medical_condition) — rare hematologic disorder initially suspected as cause of death
Forward-Looking Statements
- Innate Pharma's stock price will see a positive short-term reaction due to the lifted clinical hold. (Innate Pharma SA) — high confidence, target: 2024-01-12
- The lacutamab clinical trials (IPH4102-201 and 102) will resume enrollment and treatment without further significant delays. (lacutamab) — medium confidence, target: 2024-03-31
FAQ
What was the specific reason the FDA initially placed a partial clinical hold on lacutamab?
The FDA placed a partial clinical hold on lacutamab's IND on October 5, 2023, following a patient death in the ongoing lacutamab trials IPH4102-201 (Phase 2 TELLOMAK) and 102 (Phase 1b PTCL). The death of a patient affected by Sézary Syndrome was initially considered due to hemophagocytic lymphohistiocytosis (HLH).
When did Innate Pharma announce that the FDA lifted the partial clinical hold?
Innate Pharma announced on January 4, 2024, that the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold placed on the lacutamab IND.
What was the FDA's final determination regarding the cause of the patient's death that led to the hold?
The FDA's decision to lift the partial clinical hold was based on their review of the fatal case, which Innate Pharma, together with a steering committee of independent experts, determined to be related to aggressive disease progression and unrelated to lacutamab.
Which specific clinical trials were affected by the partial clinical hold on lacutamab?
The partial clinical hold affected Innate Pharma's ongoing lacutamab trials IPH4102-201 (Phase 2 TELLOMAK) and 102 (Phase 1b PTCL).
What is the significance of this 6-K filing for Innate Pharma's registration statements?
This Report on Form 6-K shall be deemed to be incorporated by reference in the registration statements on Form F-3 (Nos. 333-23881 and 333-265826) of Innate Pharma S.A., to the extent not superseded by documents or reports subsequently filed or furnished by the Company.
Filing Stats: 766 words · 3 min read · ~3 pages · Grade level 11.4 · Accepted 2024-01-05 06:09:11
Filing Documents
- a53877934.htm (6-K) — 13KB
- 0001157523-24-000024.txt ( ) — 14KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date: January 4, 2024 By: /s/ Herv Brailly Name: Herv Brailly Title: Interim Chief Executive Officer and Chairman of the Supervisory Board